(Q33768732)

29 July 2017

0 references

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study (English)

1 reference

29 July 2017

1 reference

7

Pinuccia Valagussa

0 references

Angela Moliterni

2

object named as

Angela Moliterni

0 references

Luca Gianni

6

object named as

Luca Gianni

1 reference

29 July 2017

5

Silvana Pilotti

1 reference

29 July 2017

Gianni Bonadonna

1

1 reference

29 July 2017

Milvia Zambetti

3

1 reference

29 July 2017

Maria Grazia Daidone

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

13 January 2005

1 reference

29 July 2017

1 reference

29 July 2017

volume

330

1 reference

29 July 2017

issue

7485

1 reference

29 July 2017

page(s)

217

1 reference

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

Dose-response effect of adjuvant chemotherapy in breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

Analysis of survival by tumor response.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=546063

1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings

30 October 2018

1 reference

12 December 2020

The evolution of paradigms for the management of breast cancer: a personal perspective

1 reference

12 December 2020

Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients

1 reference

12 December 2020

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

12 December 2020

Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results

1 reference

12 December 2020

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

10.1136/BMJ.38314.622095.8F

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference